MAPT and Alzheimer disease: In 2020, the U.S. Food and Drug Administration (FDA) approved the tau radiotracer 18F-flortaucipir (FTP) (10) to estimate the density and distribution of NFTs in adult patients with cognitive impairment who are being evaluated for AD.